Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Investor Presentation (April 2015)
20 slides from Actinogen Medical's investor presentation, Apr 13, 2015
Slide 1: Developing Xanamem for Alzheimer's Dementia
Developing Xanamem™ for Alzheimer’s Dementia For personal use only Dr. Bill Ketelbey CEO, Actinogen Medical Investor Presentation April 2015
Slide 2: Forward Statements
Forward Statements For personal use only This presentation has been prepared by Actinogen Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all inform
Slide 3: Actinogen Medical - Overview
Actinogen Medical - Overview For personal use only Developing a novel treatment for Alzheimer’s disease (AD) and its prodromal stage mild cognitive impairment (MCI) • Lead compound Xanamem™ blocks production of cortisol – the stress hormone – in the brain. A novel mechanism of action Successful earl
Slide 4: Board and Management
Board and Management For personal use only A highly experienced Board and Management team with a wealth of drug development, commercialisation and clinical research expertise Martin Rogers • Biotechnology entrepreneur and executive Chairman • Non-Executive Director of OncoSil (ASX:OSL), Chair of Rhi
Slide 5: A significant unmet need
A significant unmet need For personal use only Alzheimer’s disease is emerging as one of the most significant health challenges of our time • A person develops AD almost every minute in the US¹ • AD cost the US healthcare system $US250 billion in 2013 • Estimated to increase to US$1 trillion by 2050
Slide 6: AD consequence of a rapidly ageing population
AD consequence of a rapidly ageing population For personal use only Number of people aged 60 or over: World, • Affects nearly 36 million developed and developing countries, 1950-2050 patients worldwide • In Australia, there are currently 320,000 AD sufferers – by 2050, this is expected to rise to cl
Slide 7: The hallmarks of AD
The hallmarks of AD For personal use only Memory, language and abstract reasoning impairment with Normal • brain shrinkage – particularly hippocampus and cortex • neuronal loss • amyloid plaques • neurofibrillary tangles Alzheimer’s 7
Slide 8: Signs of AD
Signs of AD For personal use only Dementia is typically documented by decreasing performance on neuropsychological tests assessing memory, general knowledge, language, abstract reasoning and the ability to perform particular tasks requiring minimal skill: ‘ Please draw a clock. Put the hours on it a
Slide 9: Overview of Xanamem
Overview of Xanamem™ For personal use only Xanamem™ - under development as a treatment for Alzheimer's disease and prodromal Alzheimer's/mild cognitive impairment • A novel mechanism of action blocking the production of cortisol in the brain • Excess cortisol (the stress hormone) has been shown to l
Slide 10: Mechanism of action: a key differentiator
Mechanism of action: a key differentiator For personal use only Xanamem™’s novel mechanism of action sets it apart from other AD treatments 10
Slide 11: Mechanism of action: a key differentiator
Mechanism of action: a key differentiator For personal use only Xanamem™’s novel mechanism of action sets it apart from other AD treatments • The HSD1 enzyme activates cortisone, producing cortisol – the stress hormone • Xanamem™ blocks the HSD1 enzyme and prevents production of cortisol • Excess co
Slide 12: Pre-clinical data
Pre-clinical data For personal use only Xanamem™- a highly selective HSD1 inhibitor in pre-clinical animal models. • Inhibition of HSD1 improves cognition in ageing and AD models • Inhibition of HSD1 reduces Aβ plaque burden and plasma Aβ in AD models 12
Slide 13: Clinical trials overview
Clinical trials overview For personal use only Second Phase 1 study in healthy volunteers underway • Trial conducted at Linear Clinical Research, Sir Charles Gairdner Hospital Perth, Western Australia. • 40 healthy volunteers enrolled across 3 studies • First study to confirm how the body absorbs an
Slide 14: Xanamem Clinical Advisory Board
TM Xanamem Clinical Advisory Board For personal use only Powerhouse Advisory Board to drive Xanamem™’s clinical development. World experts to help design the optimum Phase II efficacy trial for Xanamem™ in early and prodromal Alzheimer’s patients Prof. Craig Ritchie Prof. Colin Masters Prof. Jeffrey
Slide 15: Pipeline
Pipeline For personal use only Xanamem™’s novel mechanism of action – blocking excess cortisol production – offers many additional possible applications relevant to diseases of the central nervous and endocrine/metabolic systems • Potential development opportunities: – Cognitive dysfunction in schiz
Slide 16: Financial profile
Financial profile For personal use only Price (AUD) Key Corporate Data: $0.095 $0.085 Market Cap: $41.34m $0.075 $0.065 Share Price $0.084 $0.055 Cash as of 31 Dec $2.05m $0.045 $0.035 2014 $0.025 Shares on issue 492m Top Ten Shareholders Percentage Edinburgh Technology Fund Limited 9.78% JK Nominee
Slide 17: Milestones
Milestones For personal use only Phase II efficacy Second study in patients Phase I Results for Phase I with AD and Mild trial trial and final Cognitive initiated preclinical study Impairment EARLY-2015 MID-2015 2016 Final Establishment of Phase II pre-clinical Xanamem™ study and protocol study fo
Slide 18: Investment highlights
Investment highlights For personal use only • Xanamem™ a potential treatment for early and prodromal AD/mild cognitive impairment • Significant unmet need in a huge and growing global market • Novel mechanism of action, targeting the stress hormone cortisol – a key differentiator • Hypothesis backed
Slide 19: Contact details
Contact details For personal use only Head Office Level 10, 15-17 Young Street, Sydney, NSW, 2000 Telephone: +61 (02) 8964 7401 Facsimile: +61 (02) 8964 7588 Email: bill.ketelbey@actinogen.com.au Twitter: @billketelbey 19
Slide 20: Thank you and questions
For personal use only Thank you and questions
Actinogen Medical — Investor Presentation (April 2015) on 6ix